专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008008608A2 METHOD OF TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM 审中-公开
标题翻译：治疗和预防继发性高血压病的方法
公开(公告)号：WO2008008608A2
公开(公告)日：2008-01-17
申请号：PCT/US2007071791
申请日：2007-06-21
申请人： PROVENTIV THERAPEUTICS LLC , CYTOCHROMA INC , BISHOP CHARLES W , CRAWFORD KEITH H , MESSNER ERIC J , PETKOVICH MARTIN P , HELVIG CHRISTIAN F
发明人： BISHOP CHARLES W , CRAWFORD KEITH H , MESSNER ERIC J , PETKOVICH MARTIN P , HELVIG CHRISTIAN F
CPC分类号： A61K31/593 , A61K9/48 , A61K31/59 , A61K31/592
摘要： The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25 -hydroxy vitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25 -hydroxy vitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25- hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25- hydroxyvitamin D during treatment comprises predominantly 25 -hydroxy vitamin D3, and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D3 for 25 -hydroxy vitamin D repletion and/or maintenance
摘要翻译：通过根据需要施用维生素D补充剂和维生素D激素替代疗法，通过增加或维持患者的25-羟基维生素D和1,25-二羟基维生素D的血液浓度来治疗iPTH的血液水平升高的方法，被披露。 25-羟基维生素D的血液浓度增加并保持在30ng / mL以上，1,25-二羟基维生素D的血液浓度增加至维持在患者正常的历史生理范围内1,25-二羟基维生素 D，而不会导致患者高钙血症，高磷酸血症或过度抑制血浆iPTH的风险显着增加。 25-羟基维生素D的血液水平在维生素D补充疗法剂量之间维持在或高于30ng / mL，1,25-二羟维生素D的血液水平维持在患者维生素D剂量之间的正常历史生理范围内激素替代疗法。在一个方面，本公开包括其中治疗期间25-羟基维生素D的血液浓度主要包含25-羟基维生素D3和/或其中所述方法包括主要或仅仅使用25-羟基维生素D补充的25-羟基维生素D3的方法， /或维护

2. 发明申请

WO2008134518A3 METHODS AND COMPOUNDS FOR VITAMIN D THERAPY 审中-公开
标题翻译：维生素D治疗方法与化合物
公开(公告)号：WO2008134518A3
公开(公告)日：2009-12-30
申请号：PCT/US2008061586
申请日：2008-04-25
申请人： CYTOCHROMA INC , PROVENTIV THERAPEUTICS LLC , PETKOVICH P MARTIN , BISHOP CHARLES W , MESSNER ERIC J , CRAWFORD KEITH H
发明人： PETKOVICH P MARTIN , BISHOP CHARLES W , MESSNER ERIC J , CRAWFORD KEITH H
IPC分类号： A61K31/59
CPC分类号： A61K31/592 , A61K9/0019 , A61K9/0053 , A61K47/14 , A61K47/44
摘要： Methods and compositions comprising 1,25-dihydroxyvitamin D2 are disclosed. A method for lowering or maintaining lowered serum parathyroid hormone in human patients including administering to said patients an effective amount of 1,25-dihydroxyvitamin D2 to lower or maintain lowered serum parathyroid hormone levels is disclosed. Dosage forms and dosing regimens are also disclosed.
摘要翻译：公开了包含1,25-二羟基维生素D2的方法和组合物。一种用于降低或维持人类患者血清甲状旁腺激素降低或降低的方法，包括向所述患者施用有效量的1,25-二羟维生素D 2以降低或维持血清甲状旁腺激素水平的降低。还公开了剂量形式和给药方案。

3. 发明申请

WO2007092755A3 TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3 审中-公开
标题翻译： 25-羟维生素D2和25-羟维生素D3处理维生素D不足和缺乏
公开(公告)号：WO2007092755A3
公开(公告)日：2007-09-27
申请号：PCT/US2007061521
申请日：2007-02-02
申请人： PROVENTIV THERAPEUTICS LLC , BISHOP CHARLES W , CRAWFORD KEITH H , MESSNER ERIC J
发明人： BISHOP CHARLES W , CRAWFORD KEITH H , MESSNER ERIC J
IPC分类号： A61K31/592 , A61K9/20 , A61K31/593 , A61P3/02 , A61P19/08
CPC分类号： A61K31/593 , A61K9/00 , A61K9/0019 , A61K9/16 , A61K9/48 , A61K9/4808 , A61K9/4858 , A61K9/4866 , A61K9/4875 , A61K31/592 , A61K47/26
摘要： Methods and compositions for treating 25-hydiOxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , or it inchides gradually administering to the patient an sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D 2 , 25- hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
摘要翻译：本文描述了用于治疗患者中的25-羟基维生素D不足和缺乏的方法和组合物。该方法包括对患者口服给药延迟的缓释制剂，该制剂包含选自25-羟基维生素D 2，25-羟基维生素D 3，25-羟基维生素D 3，或者25-羟基维生素D 2和25-羟基维生素D 3的组合，或者其逐渐向患者施用包含选自组的第一成分的无菌静脉制剂其由25-羟基维生素D 2，25-羟基维生素D 3或25-羟基维生素D 2和25-羟基维生素D 3的组合组成， SUB> 3 。

4. 发明申请

WO2007047327A2 METHODS AND ARTICLES FOR TREATING 25-HYDROXYVITAMIN D INSUFFICIENCY AND DEFICIENCY 审中-公开
标题翻译：治疗25-羟维生素D缺乏症和缺乏症的方法和文章
公开(公告)号：WO2007047327A2
公开(公告)日：2007-04-26
申请号：PCT/US2006039787
申请日：2006-10-12
申请人： PROVENTIV THERAPEUTICS LLC , BISHOP CHARLES W , CRAWFORD KEITH H , MESSNER ERIC J
发明人： BISHOP CHARLES W , CRAWFORD KEITH H , MESSNER ERIC J
IPC分类号： A61K31/59 , A61K31/593 , A61K45/06 , A61P43/00
CPC分类号： A61K31/59 , A61K9/4841 , A61K9/4858 , A61K9/4875 , A61K9/4891 , A61K31/593 , A61K45/06 , A61K2300/00
摘要： A controlled-release phapnaceutical formulation including cholecalciferol and/or ergocalciferol, a method of making the formulation, and a method of administering the formulation to treat 25-hydroxyvitamin D insufficiency or deficiency, are disclosed. The composition and method of administration preferably result in delayed release of the vitamin(s) in the ileum of the small intestine and sustained, substantially constant, release of the vitamin(s) over an extended period, e.g., at least 4 hours or more. Individual and combined dosages of 500 IU to 50,000 IU per dosage form, preferably daily, are disclosed. The compositions and methods are contemplated to exhibit one or more advantages including, but not limited to efficiency of vitamin D repletion and maintenance; mitigation or avoidance of first pass effects of the Vitamin D compounds on the duodenum; mitigation or avoidance of adverse supraphysiological surges in intralumenal, intracellular and blood levels of cholecalciferol, ergocalciferol and 25- hydroxyvitamin D and their consequences; and mitigation or avoidance of serious side effects associated with Vitamin D supplementation, namely Vitamin D toxicity.
摘要翻译：公开了包括胆钙化甾醇和/或麦角钙化醇的控释药物制剂，制备方法和施用该制剂以治疗25-羟基维生素D不足或不足的方法。组合物和给药方法优选地导致维生素在小肠回肠中的延迟释放和持续的，基本上恒定的维生素释放在延长的时间内，例如至少4小时或更长时间。公开了每剂量形式的500IU至50,000IU的个体和组合剂量，优选每天。预期组合物和方法表现出一个或多个优点，包括但不限于维生素D补充和维持的效率; 缓解或避免维生素D化合物对十二指肠的首过效应; 缓解或避免胆钙化醇，麦角钙化醇和25-羟基维生素D的肠内，细胞内和血液中的不良超生理波动及其后果; 并减轻或避免与维生素D补充相关的严重副作用，即维生素D毒性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式